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influenza, reducing morbidity and mortality rates not only for those vaccinated,
but also for the entire population by reducing the spread of the virus. In the context
of contact network epidemiology, an individual who is located in the center of the
network is more likely to become infected. Thus, vaccinating such individuals
before others would be more efficient in reducing the influenza burden.METHODS:
We show that immunizing those who have been infected in the previous season,
especially before the peak of the disease, can substantially reduce infection rates
for a wide range of influenza viruses. Using the Susceptible Infected Recovered (SIR)
compartmental model we ran 2,100,000 simulations, each reflecting two successive
influenza seasons over a 1.5 million population contact network based on the
Portland population. The second season was checked for a Random Vaccination
Policy (RVP) and when using a vaccination policy prioritizing first those who were
infected in the previous season especially before the peak (PFIP). RESULTS: When
no vaccination is offered, individuals who became infected in the previous season
have a higher probability of becoming infected in the following season. Accord-
ingly, PFIP can reduce the number of infected by up to 80% compared to RVP, even
if the cross-reactivity rate between the viruses of two seasons is as high as 60-80%.
We provide a simple tool describing the conditions when each policy should be
used.CONCLUSIONS:No CDC recommendations have ever considered the effect of
a previous season on an individual in determining future vaccination policy. The
PFIP can be achieved easily by sending pamphlets, telephone reminders or even
family doctor recommendations to those who were diagnosed by the family doctor
as suffering from influenza like illness (ILI) in the previous season.
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OBJECTIVES: The UK Government has allocated £200 million per year for three
years to fund cancer drugs in England which will be managed via the Cancer Drugs
Fund (CDF). There are ten CDFs in England which are largely managed by Cancer
Network Pharmacists. The objective of this research was to identify from the Can-
cer Network Pharmacists’ perspective what impact the CDF had made in the first
year on cancer drug usage, practice, use of resources and also their concerns if the
CDF disappeared after three years. METHODS: A semi structured questionnaire
was developed to capture quantitative and qualitative data relating to changes in
oncology drug use, clinical practice and resources for the time period 1st April 2011
to 31st March 2012.This questionnaire was also used to capture information on the
Cancer Network Pharmacists concerns if the CDF disappeared after three years.
The questionnaire was piloted with three Cancer Network Pharmacists. Telephone
interviews were undertaken with Cancer Network Pharmacists covering the ten
CDFs. The data collected was assessed and evaluated, using a thematic framework.
RESULTS: The CDF had led to a significant increase in use of some drugs and
clinical practice had changed. Workload for pharmacy both at the cancer networks
and in the hospital Trusts had increased. Attendances at clinics had increased
creating some capacity issues. The commissioning process for cancer drugs had
changed; new drugs were not commissioned unless recommended by NICE. It was
considered there would be significant risks if the CDF disappeared after three years
as it was not clear how drugs funded by the CDF would then be funded and return
to practice pre CDF would be difficult. CONCLUSIONS: The CDF had changed clin-
ical practice for the management of certain cancers. If the CDF disappeared in 2014
it was unclear how some drugs would be funded.
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OBJECTIVES: To evaluate the impact of training of dispensers on the process of
case management of ARI at community pharmacies in context to history taking
and provision of advice working at community pharmacies in Islamabad, Pakistan.
METHODS: A randomized, controlled, blinded intervention study was designed
and implemented. Before the implementation of intervention, a baseline study was
performed to assess the process of case management for ARI at community phar-
macies. The study population included all community pharmacy outlets in Islam-
abad. After data collection, data was analyzed. The result of the study revealed that
the overall process of disease management of ARI at community pharmacies in
Pakistan is not satisfactory. Pharmacies of Islamabad which were visited in pre
intervention phase (118) were divided into two geographical regions A (interven-
tion) and B (control). From which thirty pharmacies were selected randomly from
each region. The targeted group of the interventions was drug sellers. Keeping in
view the results of the base line study an educational intervention was designed to
improve the case management of ARI at community pharmacies in Pakistan.
RESULTS: No significant difference (p  0.05) was seen in the process of history
taking and advice provision in case of ARI management at community pharmacies
between pre and post control groups. On the other hand significant difference in
the process of history taking and provision of advice for ARI was observed in the
intervention group before and after training. CONCLUSIONS: The study has high-
lighted that improvements in the current dispensing practices at community phar-
macies are possible through appropriate educational interventions. The dispens-
ers have the potential to provide fast and low cost health care to the masses in the
country where the presence of doctors and qualified pharmacist is low; to date they
are an untapped and underutilized source in the country.
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OBJECTIVES: To analyze the formation of formulary for specific drugs require-
ments at medical organizations(MOs) in Kazakhstan. METHODS: Questionnaires
were filled in by the members of the formulary committees (FC) at MOs (79 ones
from 4 regions of KZ) with different nosologies which had developed service; mor-
bidity recording; state drug provision system through single distributors (SD).
RESULTS: FCs mainly consisted of 34 % deputies of head doctors, 23 % pharmacists,
11 % nurses, 10 % head doctors, 8 % doctors, 1 % accountants; in only 1% of the MOs
clinical pharmacologists were amongst FCs. Moreover, 72 % had not trained in the
drug management; 12 % had experience a long time ago; 10 % improved qualifica-
tions in 2009-2010. The lists composed considering the profile and thus the specific
needs of the MOs (77 %); lists of drugs provided by the SD (58 %); the Republican
Formulary (44 %). 41 % of the MOs had access to the state register; just the third of
them had instructions with authorities for the members. Similar number of the
MOs had guidance/algorithms for filling in applications and accounts conductions.
The applications were filled in considering the extents of previous consumptions
(81 %); medical regimen (72 %); the patients’ number (70%); left amount of drugs
(63%); 94 % highlighted the toxicity to be considered for future lists. Amongst ad-
ditional factors, experience in specific drugs usage was pointed out (56 %); 18 %
claimed the insufficiency of information on tenders and vague choice criteria.
Noteworthy, 15 % stated the lobbying of some of drugs manufacturers.
CONCLUSIONS: Regardless to drugs provision by the state, there are obstacles in
the formation of FCs and formularies lists at the MOs: no presence of clinical
pharmacologists, no consideration of specific needs, poor training of the personnel.
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OBJECTIVES: To develop the clinical practice guideline major depressive disorder
for general practitioners in primary and secondary health care setting included the
diagnosis, differential diagnosis, severity classification and medical treatments.
METHODS:A list of 13 key elements of a CPG development process were developed
that consisted of: 1) setting the review teams; 2) determining the problems; 3)
determining health outcomes; 4) evidence based literature review; 5) meeting to
draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by
experts; 8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for
CPG training; 11) preparing for CPG training; 12) evaluating; and 13) improving the
CPG related with evaluated results. RESULTS: There were 3 main processes in
clinical practice guideline major depressive disorder for general practitioners in
primary and secondary health care setting (CPG-MDD-GP) which were 1) Assess-
ment of major depressive disorder (clinical assessment using 9Q screening tool and
DSM-TR diagnostic criteria, differential diagnosis, diagnosis for major depressive
disorder and coding of diagnosis) 2) Management of major depressive disorder and
3) Management of hospitalized patients. General practitioners were satisfied with
the CPG-MDD-GP in trial phase. A total of 416 general practitioners in all provinces
were trained to use the CPG-MDD-GP then they would be followed and evaluated.
Psychiatrists in psychiatric hospitals/ institutes would be available for consultation
from the general practitioners. CONCLUSIONS: The CPG-MDD-GP should be dis-
tributed to all general practitioners in primary and secondary health care setting.
Next step, it would be useful for developing the CPG for MDD in the tertiary health
care setting.
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OBJECTIVES: Patients access to new drugs is particularly a challenging task in UK.
English Primary Care Trusts (PCT) play a key role in facilitating the new drug’s
entry. The PCTs differ from each others through their behaviors and characteris-
tics. The main purpose of this study is to bifurcate a total of 152 PCT in similar
clusters having homogenous behavior, applying several clustering approaches,
and to compare the different approaches METHODS: All available information
about the PCTS is obtained from public sources and one key data base. A total of
64 variables were identified and classified into 5 groups according to population’s
profile, prescription and patient’s characteristics, economic, financial as well as
organizational criteria. We applied three kinds of clustering approaches: the two
first, namely k-means (implemented both directly and indirectly) and Hierarchical
Agglomerative Clustering (HAC) are traditional ones while the third, namely Self
Organizing Map (SOM) is a variant of neural network architectures. Finally, contin-
gency analysis and khi-square statistics were considered to encircle both depen-
dencies and similarities between clusters RESULTS: Preliminary estimates have
identified five clusters (for each method) that are different in their intrinsic char-
acteristics. Contingency results reflect strong dependence between the direct k-
mean and both HAC and SOM: indeed clusters are not very widely scattered be-
tween them. The chi-square (p-value) test corroborates their homogeneity. The
indirect K-means reflects heterogeneity in cluster’s dispersions also confirmed by
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the chi-square test CONCLUSIONS: Despite the fact that clusters are generated
from different approaches and have no similar characteristics, a plausible corre-
spondence seems to develop between them. Thus, our investigations may help in
identifying countless promising market strategies facilitating the access of new
drugs according to UK regional standards.
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OBJECTIVES: To examine inequalities in health service utilisation in urban Paki-
stan. This analysis investigates how household economic status, duration of illness
and distance to a provider influence health service utilisation in Pakistan.
METHODS: The study uses data from the Pakistan Socioeconomic Survey (PSES)
and analysis is based on 1,407 individuals who belong to 855 urban households.
Health care providers are classified into public hospitals, other public providers,
private doctors/clinics and other private providers. Household economic status is
measured by a wealth index constructed using data from the survey on ownership
of durable assets and housing conditions. Principal components analysis (PCA) is
used to construct the index. Multinomial logistic regression is used to investigate
the effects of various characteristics of individuals/households on health service
utilisation in Pakistan. RESULTS:Overall, 79.6% of those reporting any health com-
plaint sought health care. A large gap in health service utilisation exists between
poorest patients (60.5%) and richest patients (84.9%). Almost three-fourth patients
visited private providers; 57.3% visited private doctors/clinics and 15.7% visited
other private providers. The remaining one-fourth patients visited public providers
(19.7% visited public hospitals and 7.2% other public providers). Multinomial logis-
tic regression reveals that poorest patients are significantly more likely (p0.10) to
visit public hospitals whereas patients of poorest, poor, middle and rich house-
holds are significantly less likely to visit private doctors/clinics compared to mem-
bers of richest households controlling for other factors such as education, occupa-
tion, duration of illness, distance to a provider and residence. An additional day of
illness significantly (p0.01) increases the likelihood of visiting public hospitals
and private doctors/clinics. The distance travelled to visit a provider shows a sig-
nificant positive (p0.01) and negative association with visiting public hospitals
and other private providers respectively. CONCLUSIONS: Large gaps exist in health
service utilization in urban Pakistan.
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OBJECTIVES: Generate preliminary estimates of active health care professional
(HCP) time required /potential time and cost savings between SC vs. IV rituximab
processes at the care unit and pharmacy in sites participating in T&M sub-study to
MO25455 trial (ClinicalTrials.gov identifier NCT01461928). METHODS: As part of an
ongoing multi-country, multi-centre, prospective, T&M study run as a sub-study to
MO25455, one interview with a nurse and pharmacy member was conducted per
site, using a structured questionnaire to elicit practice pattern flow and time esti-
mates for rituximab-related tasks for both IV and SC processes. Estimates of SC
injection time were obtained from the Spark-Thera Phase Ib trial (BP22333) (in the
absence of staff-elicited time estimates). Estimated total time/cost was calculated
as the sum of individual task times/costs. UK salary costs were assumed. Results
were pooled and descriptive statistics were calculated. RESULTS:Median total HCP
time for IV vs. SC processes was estimated at 57 and 26 minutes, respectively,
equivalent to approximately £79 and £37 (estimated 54% reduction with SC). For IV,
process time is taken up by premedication (27%) and rituximab pharmacy recon-
stitution (18%), with the remaining 55% distributed across other care unit tasks. For
SC, premedication (57%), injection (24%) and rituximab pharmacy dispensing (19%)
constitute the whole process. Potential time savings are expected because of avoid-
ing tasks related mainly to infusion line (dis)connection, infusion initiation/dose
escalations, and IV pharmacy reconstitution, which is only partially being replaced
by SC injection. CONCLUSIONS: A switch from IV to SC rituximab potentially re-
sults in important care unit and pharmacy time savings to be reinvested in improv-
ing overall patient care. Patients could potentially be moved out of the chemother-
apy care unit to receive SC administration in other settings and free up valuable
chair time, thereby increasing the unit’s throughput and overall efficiency. Data of
the T&M study is awaited.
PHS84
ANALYZING PHARMACEUTICAL EXPENDITURE IN GREECE:UNWINDING
ARIADNE’S CLUE
Siskou O1, Kaitelidou D2, Schneider M3, Kalogeropoulou M1, Tsavalias K1, Passaloglou S4,
Kouli E1, Galanis P1, Kontozamanis V1, Liaropoulos L1
1National and Kapodistrian University of Athens, Athens, Greece, 2National and Kapodistrian
University of Athens, Athnes, Greece, 3BASYS, Augsburg, Germany, 4Novartis Hellas,
Metamorfosi Athens, Greece
OBJECTIVES: To compile pharmaceutical expenditure in Greece by financing
scheme and type of provider, in order to investigate areas that cost containment
measures could be monitored effectively. METHODS: The method used for the
estimation of pharmaceutical expenditure is based on the System of Health Ac-
counts 2011 set by OECD, EUROSTAT, and WHO, taking into consideration the
national needs for data reporting both in outpatient and inpatient settings. Data
were reported by type of provider, including hospital pharmacies, Social Security
Funds (SSF) pharmacies, private pharmacies and local authorities social pharma-
cies as well as by financing schemes, including SSFs, private payments and NHS
payments. Additionally, pharmaceutical data are analysed using the new interna-
tional classification of Factors of Health Care Provision. Estimates were obtained
for 2009 & 2010. RESULTS: Total pharmaceutical expenditure-TPE (outpatient &
inpatient) in Greece, decreased by 9,3% between 2009 & 2010. Pharmaceutical out-
patient expenditure covered by SSF was estimated at €5.1 bl for 2009 (2.2% of GDP)
and €4.46 bl for 2010 (2% of GDP). Less than 8% of outpatient pharmaceutical ex-
penses covered by SSF, concern pharmaceuticals dispensed by NHS & SSF pharma-
cies. These public pharmacies dispense expensive pharmaceuticals (for serious
and chronic diseases) at significantly lower prices than private pharmacies. Inpa-
tient pharmaceutical expenses decreased by 9,1% (€1.2 bl in 2009 and €1.1 bl in
2010), representing 15.3% of total pharmaceutical expenditures (outpatient and
inpatient), a proportion similar to the mean of other EU countries estimated at
about 17%. Measures to control the volume of consumption were recently intro-
duced via e-prescribing and the set up of controlling mechanisms. CONCLUSIONS:
Reductions in pharmaceutical expenditure are correlated mainly to price reduc-
tions and less to a decrease in volume of consumption. Measures concerning phar-
maceutical cost containment have to be reorganised not only concerning price and
volume but also concerning new –innovative ways of distributing pharmaceuticals.
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OBJECTIVES: We provide an estimate of public expenditures on cancer prevention
in Alberta. Our estimate covers all three levels of government – federal, provincial,
and municipal. METHODS: Public cancer prevention is a government activity
whose purpose is to expressly reduce the future incidence of cancer. As part of
a wider initiative, we conducted a survey of ministries, in search of all programs
whose express purpose was to promote health and prevent illness. We searched
web pages, ministry annual reports and federal and provincial budget papers. We
collected data on program type, type of intervention, and program cost. We then
verified the results with each ministry. We sorted the data by risk factors, and
selected those risk factors that were related to cancer. RESULTS: Expenditures for
those risk factors that are related to cancer are shown in Table 1. In total expendi-
tures on these risk factors were $206. Of this, about two-thirds were expenditures
that were incurred by non-health, provincial ministries. The risk factor with the
highest preventive expenditures was environmental health. CONCLUSIONS: In
Alberta, all levels of government spent $206 per person on risk factors that can
prevent cancer, mostly in the long run. Without a cost – effectiveness analysis, we
cannot say that this amount is too much or too little. However with this data, and
a cost effectiveness analysis, we can in fact say whether we are spending too much
or too little.
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OBJECTIVES: To describe resource utilization and costs associated with treating
surgically managed non-small-cell lung cancer (NSCLC) patients in Ontario, Can-
ada; to compare characteristics and average costs of patients treated with adjuvant
therapy to surgery alone; and to compare resource utilization and costs across
health care regions. METHODS: A population-based retrospective cohort study of
surgically resected NSCLC patients, diagnosed from Ontario Cancer Registry be-
tween 2004 and 2006, was identified using administrative health care data. Patients
were followed for four years from date of surgery (to represent the cohort imme-
diately affected by the change in clinical practice -- recommended adjuvant cispla-
tin-based treatment). Cost estimates (2001 CAN dollars) were derived from admin-
istrative data and the literature. RESULTS: Patients who received adjuvant
chemotherapy in addition to surgery were younger and had a less severe burden of
co-morbid disease than patients treated with surgery alone (p0.001). Geographic
variation was found with respect to age, Charlson score, and socioeconomic status.
Rates of chemotherapy, the proportion of patients who received any imaging
scans, hospitalizations, specialist visits, emergency room visits, mean number of
imaging scans, general physician visits, and blood transfusions all varied signifi-
cantly among geographic regions. The average cost of a patient treated with sur-
gery and adjuvant chemotherapy was $36,617.70 and was significantly higher than
the average cost of a patient treated with surgery alone ($29,071.60) (p0.0001).
Among regions, the average cost of patients treated with chemotherapy was sim-
ilar, while the average cost of patients treated with surgery alone varied signifi-
cantly (p0.0008). CONCLUSIONS: Differences exist in the average cost of treating
a resectable NSCLC patient with surgery and adjuvant chemotherapy in compari-
son with surgery alone. This phase IV population-based study demonstrates a
similar cost per patient as evidenced in the randomized controlled trials. Under-
standing why these patients incur higher average costs is important with respect to
delivering cost-effective treatment.
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